Drug intelligence / Profile preview

THBP4

Development stage: Preclinical
Lead developer: Manglayatan University
Modality: Small Molecules

Overview

THBP4 (also known as THBP-4) is a novel tetrahydrobenzopyran derivative synthesized and evaluated for its potential anticancer activity. It belongs to a series of 2-(toluenesulfonamido)-3-cyano-7,7-dimethyl-4-substituted phenyl-5,6,7,8-tetrahydrobenzopyran-5-one derivatives developed by researchers at Manglayatan University and St. Mary's College of Pharmacy. THBP4 has been evaluated in vitro against MCF-7 breast cancer cells using the MTT assay to determine its cytotoxic potential and IC50 values, as part of an effort to identify potent lead compounds for breast cancer therapy.

Targets

Actin filament proteins

Beyond the preview

Go deeper on THBP4.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on THBP4.

Explore the full profile